1268 N. Lakeview Ave., Anaheim, CA 92807, U.S.A.   
Phone: (714) 693-7788 Toll Free: 1-800-222-9880 Fax: (714) 693-3838 www.tecodiag.com Email:tecodiag@tecodiag.com   
Updated 510K summary   
Teco CX3 Reagent Set for SYNCHRON CX   
Contact Name: Jian Vaeches   
Phone Number: 714-693-7788 ext.131   
Prepared Date: 03/20/2006

1268 N. Lakeview Ave., Anaheim, CA 92807, U.S.A. Phone: (714) 693-7788 Toll Free: 1-800-222-9880 Fax: (714) 693-3838 www.tecodiag.com Email:tecodiag@tecodiag.com

# Device Name

The device trade names and common/classifications name are:

<table><tr><td>Device Trade Name</td><td>Common/Classification Name</td></tr><tr><td>Teco CX3 Reagent Set for SYNCHRON CX System</td><td>BUN, CALCIUM, CREATININE ,GLUCOSE REGENTS</td></tr></table>

# Address and Registration

The address and registration number of the manufacturer site for Teco CX3 Reagent Set for SYNCHRON CX System:

TECO Diagnostics 1268 N. Lakeview Ave. Anaheim, CA 92807, U.S.A. FDA Registration # 1832216

# Device Classs

CDQ CC Teco CX3 Reagent Set has been classified as Class II with Product Code LPP, JFP, CGX, CGA "in vitro" diagnostics reagent set having the classification number: 21 CFR. 862.1770, 21 CFR 862.1145, 21 CFR 862.1225, 21 CFR 862.1345. This is the description available from the classification names listed in the CDRH Home Page- Listing Database.

# Predicate Device Information

The predicate device is Teco BUN Liquid, Teco Calcium Color, Teco Creatinine and Teco Glucose Liquid Reagent.

The 510 (K) approval letter is provided in Appendix I. 510(K) #: K981106, K864741, K880629, K863926. Approval Date: 04-16-1998, 01-09-1987, 03-23-1988, 11-13-1986

# Labeling and Intended Use

Draft labels and Instructions for use can be found in appendix A.

Intended Use   
Teco CX3 Reagent Set for SYNCHRON CX is intended for the quantitative determination of BUN, Calcium, Creatinine and Glucose in serum on Beckman CX3 System.

# Device Description and Comparison

The Teco CX3 Reagent Set for SYSNCHRON CX designed for use on the Beckman CX System. The Reagent Set includes BUN, Calcium, Creatinine and Glucose.

Method Comparison of Teco CX3 Reagent Set for SYNCHRON CX to Teco BUN Liquid, Teco Calciun Color, Teco Creatinine and Teco Glucose Liquid following the guidelines of NCCLS Guideline EP9-A2 was conducted.

Comparison with predicate: Similarities   
Intended use.   
Sample Handling Subsystem. Operational Environment   
Performance.   
1268 N. Lakeview Ave., Anaheim, CA 92807, U.S.A.   
Phone: (714) 693-7788 Toll Free: 1-800-222-9880 Fax: (714) 693-3838 www.tecodiag.com Email:tecodiag $@$ tecodiag.com

Differences   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Predicate Device</td><td rowspan=1 colspan=1>Candidate Device</td></tr><tr><td rowspan=1 colspan=1>Packaging Size</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>BUN</td><td rowspan=1 colspan=1>5 x 25ml &amp;5x5ml</td><td rowspan=1 colspan=1>500 ml</td></tr><tr><td rowspan=1 colspan=1>Calicium</td><td rowspan=1 colspan=1>4 x 120 ml</td><td rowspan=1 colspan=1>500 ml</td></tr><tr><td rowspan=1 colspan=1>Creatinine</td><td rowspan=1 colspan=1>4 x 120 ml</td><td rowspan=1 colspan=1>2000 ml</td></tr><tr><td rowspan=1 colspan=1>Glucose</td><td rowspan=1 colspan=1>4 x 120 ml</td><td rowspan=1 colspan=1>500 ml</td></tr><tr><td rowspan=1 colspan=1>Analyzer</td><td rowspan=1 colspan=1>General Chemistry Analyzers</td><td rowspan=1 colspan=1>SYSCHRON CX3</td></tr><tr><td rowspan=1 colspan=1>Components</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=5 colspan=1>BUN</td><td rowspan=1 colspan=1>Tris Buffer 100 mmol</td><td rowspan=5 colspan=1>Urease &gt;592 U/ml</td></tr><tr><td rowspan=1 colspan=1>2-Oxoglutarate 5 mmol</td></tr><tr><td rowspan=1 colspan=1>Urease &gt;20,000 U/L</td></tr><tr><td rowspan=1 colspan=1>GLDH &gt; 1500 U/L</td></tr><tr><td rowspan=1 colspan=1>NADH 0.25 mmol/L</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Predicate Device</td><td rowspan=1 colspan=1>Candidate Device</td></tr></table>

<table><tr><td rowspan=3 colspan=1>Calcium</td><td rowspan=1 colspan=1>O-Cresolphthalein Complexone 0.14 mM</td><td rowspan=3 colspan=1>Arsenazo III 0.15 mml/L</td></tr><tr><td rowspan=1 colspan=1>8-Hydroxyquinoline 13 mM</td></tr><tr><td rowspan=1 colspan=1>Diethylamide 363 mM</td></tr><tr><td rowspan=2 colspan=1>Creatinine</td><td rowspan=1 colspan=1>Picric Acid 10mM</td><td rowspan=1 colspan=1>Picric Acid 50mM</td></tr><tr><td rowspan=1 colspan=1>Sodium Hydroxide 240mM</td><td rowspan=1 colspan=1>Sodium Hydroxide 0.188 mM</td></tr><tr><td rowspan=4 colspan=1>Glucose</td><td rowspan=1 colspan=1>Glucose Oxidase 15 u/ml</td><td rowspan=1 colspan=1>Glucose Oxidase 590 u/ml</td></tr><tr><td rowspan=1 colspan=1>Peroxidase 1.2 u/ml</td><td rowspan=1 colspan=1>Ethanol 10%</td></tr><tr><td rowspan=1 colspan=1>4-Aminoantipyrine 0.38 mM</td><td rowspan=1 colspan=1>Potassium Iodide 0.04 mM</td></tr><tr><td rowspan=1 colspan=1>p-Hydroxybenzene Sulfonate 10 mM</td><td rowspan=1 colspan=1></td></tr></table>

# Standard/ Guidance Document Referenced (if applicable)

NCCLS EP5-A—Evaluation of Precision Performance of Clinical Chemistry Devices NCCLS EP6-A--- Evaluation of Linearity of Quantitative Analytical Methods NCCLS EP9-A---Method Comparison and Bias Estimation Using Patient Samples

# Test Principle

BUN (Urea Nitrogen) is hydrolyzed by urease to produce ammonium and bicarbonate which resulted in the increase of solution conductivity which is directly proportional to the concentration of BUN present in the test.

Calcium reacts with Arsenazo to form an bluish-purple colored chromophore which is measured spectrophotometrically at $6 5 0 \ \mathrm { n m }$ . A reagent blank reading is taken just prior to sample injection, and a final absorbance reading is taken 21 seconds later. The differential absorbance, corrected for the reagent blank, is directly proportional to the calcium concentration.

Creatinine from the sample combines with the reagent to produce a red color complex. Absorbance reading is taken at both ${ \mathfrak { s } } 2 0 { \mathfrak { n } } { \mathfrak { m } }$ and ${ 5 6 0 } \mathrm { n m }$ at 25.6 seconds after picking up sample. The differential absorbance has been shown to be a direct measure of the concentration of creatinine in the sample.

SYSNCHRON CX3 determines glucose concentration by an oxygen rate method using a glucose Oxygen electrode. The rate of oxygen depletion is proportional to the glucose concentration in the samples.

1268 N. Lakeview Ave., Anaheim, CA 92807, U.S.A. Phone: (714) 693-7788 Toll Free: 1-800-222-9880 Fax: (714) 693-3838 www.tecodiag.com Email:tecodiag@tecodiag.com

# Substantial Equivalence

The Teco CX3 Reagent Set for SYNCHRON CX System is substantially equivalent to other devices legally marketed in the United States. We have compared TECO Diagnostics Teco CX3 Reagent Set for SYNCHRON CX System to TECO Diagnostics Teco BUN Liquid, Teco Calcium Color, Teco Creatinine and Teco Glucose Liquid Reagent for Hitachi.The 510 (K) numbers are K981106, K864741, K880629, and K863926. Both devices are for the quantitative determination of the same analyst in serum.

# Summary of Design Control Activities

The risk analysis method used to assess the impact of modifications was a Failure Modes and Effects Analysis (FMEA). The design verification tests that were performed as a result of this risk analysis assessment are listed in table 1&2 below. The tests data can also be found in appendix C through F.

# 1.Table 1 - Performance Characteristics (Human Serum)

BUN:   

<table><tr><td>Feature</td><td colspan="2">Predicate Device</td><td colspan="3">Candidate Device</td></tr><tr><td>Precision Within-Day</td><td rowspan="3">Sample 1 N=20 CV%=2.62</td><td rowspan="3">Sample 2 N=20 Mean=51.8 SD=0.74</td><td>Sample 1 N=25</td><td>Sample 2 N=25</td><td>Sample 3 N=25</td></tr><tr><td>Mean=12.9 SD-0.33</td><td>Mean=18 SD=0.46 CV%=2.5</td><td>Mean=49 SD=0.91</td><td>Mean=97.5 SD=1.3</td></tr><tr><td>CV%=1.43 Sample 1 Sample 2 N=20 N=20 Mean-12.4 Mean=44.6</td><td>Sample 1 N^=25 Mean=18</td><td>CV%=1.9 Sample 2 N=25 Mean=49</td><td>CV%=1.3 Sample 3 N=25 Mean=98</td></tr></table>

Teco CX3 Reagent Set, the acceptability of $\mathbf { C V \% }$ in BUN test is within $8 \%$

Calcium:   

<table><tr><td>Feature</td><td>Predicate Device</td><td colspan="3">Candidate Device</td></tr><tr><td>Precision Within-Day</td><td>Sample 1 N=20 N=20 Mean=9.1 SD=0.39 CV%=4.3</td><td>Sample 2 N=25 Mean=13.7 SD=0.02 CV%=0.2</td><td>Sample 1 Sample 2 N=25 Mean=9.1 Mean=12.3 SD=0.08 SD=0.11 CV%=0.9 CV%=0.9</td><td></td><td>Sample 3 N=25 Mean=14 SD=0.16 CV%=0.8</td></tr><tr><td>Day to Day</td><td>Sample 1 N=20 Mean=9.2 SD=0.21 CV%=2.2</td><td>Sample 2 N=20 Mean=13.3 SD=0.32 CV%=2.4</td><td>Sample 1 N=25 Mean=9.1 SD=0.09 CV%=1.0</td><td>Sample 2 N=25 Mean=12.4 SD=0.14 CV%=1.1</td><td>Sample 3 N=25 Mean=14 SD=0.14 CV%=1.0</td></tr></table>

Teco CX3 Reagent Set, the acceptability of $\mathbf { C V \% }$ in Calcium test is within $5 \%$

Creatinine:   

<table><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=4>Predicate Device</td><td rowspan=1 colspan=1>Candidate Device</td></tr><tr><td rowspan=5 colspan=1>PrecisionWithin-DayDay to Day</td><td rowspan=5 colspan=4>Sample 1           Sample 2N=20              N=20Mean=1.9         Mean=8.2SD=0.05           SD=0.6CV%=2.6          CV%=7.3Sample 1           Sample 2N=20              N=20Mean=2.0         Mean=8.2SD=0.2            SD=0.4CV%=10          CV%=4.6</td><td rowspan=1 colspan=1>Sample 1    Sample 2      Sample 3N=25        N=25         N=25Mean=1.3    Mean=6.4    Mean=20</td></tr><tr><td rowspan=4 colspan=1>SD=0.04     SD=0.11       SD=0.35CV%=2.7     CV%=1.6     CV%=1.7Sample 1     Sample 2      Sample 3N=25         N=25           N=25Mean=1.3    Mean=6.6     Mean=19.9SD=0.03      SD=0.24      SD=0.33CV%=2.2    CV%=3.7      CV%=1.6</td></tr><tr><td rowspan=1 colspan=1>−</td></tr><tr><td rowspan=1 colspan=2></td></tr><tr><td rowspan=1 colspan=3></td></tr></table>

Teco CX3 Reagent Set, the acceptability of $C V \%$ in Creatinine test is within $1 0 \%$

Glucose:   

<table><tr><td>Feature</td><td colspan="2">Predicate Device</td><td colspan="3">Candidate Device</td></tr><tr><td>Precision Within-Day</td><td rowspan="6">Sample 1 N=20</td><td>Sample 2 N=20</td><td>Sample 1 N=25</td><td>Sample 2 N=25</td><td>Sample 3 N=25</td></tr><tr><td>Mean=87 SD=4.2</td><td>Mean=282 SD=5.4</td><td>Mean=78 SD=2.0</td><td>Mean=255 SD=3.4</td><td>Mean=735 SD=9.8</td></tr><tr><td>CV%-4.8</td><td>CV%=1.9</td><td>CV%=2.5</td><td>CV%=1.3</td><td>CV%=1.5</td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Sample 1 N=20</td><td>Sample 2 N=20</td><td>Sample 1 N=25</td><td>Sample 2 N=25</td><td>Sample 3 N=25</td></tr><tr><td>Mean=85 SD=3.7 SD=9.6</td><td>Mean=287</td><td>Mean=79 SD=2.6</td><td>Mean=262 SD=5.9</td><td>Mean=734 SD=8.7</td></tr></table>

Teco CX3 Reagent Set, the acceptability of CV% in Glucose test is within $1 0 \%$

Table 2-Performance Characteristics (Human Serum) BUN:   

<table><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>Candidate Device</td><td rowspan=1 colspan=1>Predicate Device</td></tr><tr><td rowspan=1 colspan=1>Linearity</td><td rowspan=1 colspan=1>3 to 102 mg/dL</td><td rowspan=1 colspan=1>up to 80 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Accuracy</td><td rowspan=1 colspan=1>R=0.99Y=1.00 -0.911</td><td rowspan=1 colspan=1>R=0.99Y=0.962 X - 0.721</td></tr><tr><td rowspan=1 colspan=1>Expect values/Reference range</td><td rowspan=1 colspan=1>15-39 mg/dL</td><td rowspan=1 colspan=1>8-23 mg/L</td></tr></table>

Teco CX3 Reagent Set BUN test, Acceptance Criteria of Accuracy: $\mathbf { r } > \mathbf { 0 . 9 5 }$ ; Slope: 0.97-1.1

Calcium:   

<table><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>Candidate Device</td><td rowspan=1 colspan=1>Predicate Device</td></tr><tr><td rowspan=1 colspan=1>Linearity</td><td rowspan=1 colspan=1>1.0 to 15 mg/dL</td><td rowspan=1 colspan=1>up to 20 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Accuracy</td><td rowspan=1 colspan=1>R=0.96Y=1.07X+0.60</td><td rowspan=1 colspan=1>R=0.97Y=0.94 X+ 0.53</td></tr><tr><td rowspan=1 colspan=1>Expect values/Reference range</td><td rowspan=1 colspan=1>8.4-10.2 mg/dL</td><td rowspan=1 colspan=1>8.5-10.5 mg/dL</td></tr></table>

Teco CX3 Reagent Set Calcium test, Acceptance Criteria of Accuracy: $\mathbf { r } > \mathbf { 0 . 9 0 }$ ; Slope: 0.90-1.1

Creatinine:   

<table><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>Candidate Device</td><td rowspan=1 colspan=1>Predicate Device</td></tr><tr><td rowspan=1 colspan=1>Linearity</td><td rowspan=1 colspan=1>0.2 to24g/dL</td><td rowspan=1 colspan=1>Up to 25 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Accuracy</td><td rowspan=1 colspan=1>R=0.99Y=0.97 -0.11</td><td rowspan=1 colspan=1>R=0.99Y=0.96 X+ 0.06</td></tr><tr><td rowspan=1 colspan=1>Expect values/Reference range</td><td rowspan=1 colspan=1>0.6-1.3 mg/dL</td><td rowspan=1 colspan=1>Male: 0.9-1.5 mg/dLFemale: 0.7-1.37 mg/dL</td></tr></table>

eco CX3 Reagent Set Creatinine test, Acceptance Criteria of Accuracy: $\mathbf { r } > \mathbf { 0 . 9 6 }$ ; Slope: 0.90-1.1

Glucose:   

<table><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>Candidate Device</td><td rowspan=1 colspan=1>Predicate Device</td></tr><tr><td rowspan=1 colspan=1>Linearity</td><td rowspan=1 colspan=1>30 to 750 mg/dL</td><td rowspan=1 colspan=1>up to 500 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Accuracy</td><td rowspan=1 colspan=1>R=0.99Y=0.96X+0.36</td><td rowspan=1 colspan=1>R=0.99Y=1.02 X+3.1</td></tr><tr><td rowspan=1 colspan=1>Expect values/Reference range</td><td rowspan=1 colspan=1>70-105 mg/dL</td><td rowspan=1 colspan=1>70-106 mg/dL</td></tr></table>

Teco CX3 Reagent Set Glucose test, Acceptance Criteria of Accuracy: $\mathbf { r } > \mathbf { 0 . 9 0 }$ ; Slope: 0.85-1.1

# MAR 2 7 2006

Ms. Jian Vaeches Teco Diagnostics 1268 N. Lakeview Ave Anaheim, CA 92807

Re: k060120 Trade/Device Name: Teco CX3 Reagent Set for SYNCHRON CX System Regulation Number: 21 CFR $\ S$ 862.1770 Regulation Name: Urea nitrogen test system Regulatory Class: Class II Product Code: CDQ, CIC, CGX, CGA Dated: March 16, 2006 Received: March 16, 2006

Dear Ms. Vaeches:

We have reviewed your Section $5 1 0 ( \mathrm { k } )$ premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devishat have beeeassif rance with the provisions  theFederal FooD and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class II (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mcan that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with al the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2 -

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0484. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

![](images/15529847787c7cfa1bca8580cf9a76c2ad3e2956e63f322baa17365c19cfc042.jpg)

Alberto Gutierez, Ph.D.   
Director   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device Evaluation and Safety   
Center for Devices and Radiological Health

# Indications for Use

510(k) Number (if known): _k060120

Device Name: Teco CX3 Reagent Set for SYNCHRON CX System

Indications For Use: Teco CX3 Reagent Set for SYNCHRON CX System is intended for the quantitative determination of BUN, Calcium, Creatinine and Glucose in serum on Beckman CX3 System.

BUN measurements are used in the diagnosis and treatment of certain renal and metabolic diseases.

Calcium measurements are used in the diagnosis and treatment of parathyroid diseases, a variety of bone diseases, chronic renal and tetany.

Creatinine measurements are used in the diagnosis and treatment of renal diseases, in monitoring renal dialysis, and a calculation basis for measuring other urine analytes.

Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders, including diabetes melitus, neonatal hypoglycemia and idiopathic hypoglycemia, and pancreatic islet carcinoma.

This reagent set is intended for in vitro diagnostic use only.